MDxHealth Licenses Prognostic Prostate Cancer Biomarker From Philips

Jun 06, 2018

|

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a worldwide licensing agreement with Philips for the rights to manufacture and market Philips' recently validated phosphodiesterase-4D7 prostate cancer biomarker as a prognostic test.

The financial terms of the agreement have not been disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

MDxHealth Licenses Prognostic Prostate Cancer Biomarker From Philips

To read the full story....

Breaking News

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Snibe Diagnostic Obtains CE Mark for HIV Chemiluminescence Immunoassay

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

FDA Grants EUAs for SARS-CoV-2 Tests From Clinical Enterprise, Qorvo Biotechnologies

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Sponsorships